The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia
Open accessAbstract
CONTEXT: The contiguous gene deletion syndrome (CAH-X) was described in a subset (7%) of congenital adrenal hyperplasia (CAH) patients with a TNXA/TNXB chimera, resulting in deletions of CYP21A2, encoding 21-hydroxylase necessary for cortisol biosynthesis, and TNXB, encoding the extracellular matrix glycoprotein tenascin-X (TNX). This TNXA/TNXB chimera is characterized by a 120-bp deletion in exon 35 and results in TNXB haploinsufficiency, disrupted TGF-β signaling, and an Ehlers Danlos syndrome phenotype. OBJECTIVE: The objective of the study was to determine the genetic status of TNXB and resulting protein defects in CAH patients with a CAH-X phenotype but not the previously described TNXA/TNXB chimera. Design, Settings, Participants, and Intervention: A total of 246 unrelated CAH patients were screened for TNXB defects. Genetic defects were investigated by Southern blotting, multiplex ligation-dependent probe amplification, Sanger, and next-generation sequencing. Dermal fibroblasts and tissue were used for immunoblotting, immunohistochemical, and coimmunoprecipitation experiments. MAIN OUTCOME MEASURES: The genetic and protein status of tenascin-X in phenotypic CAH-X patients was measured. RESULTS: Seven families harbor a novel TNXB missense variant c.12174C>G (p.C4058W) and a clinical phenotype consistent with hypermobility-type Ehlers Danlos syndrome. Fourteen CAH probands carry previously described TNXA/TNXB chimeras, and seven unrelated patients carry the novel TNXB variant, resulting in a CAH-X prevalence of 8.5%. This highly conserved pseudogene-derived variant in the TNX fibrinogen-like domain is predicted to be deleterious and disulfide bonded, results in reduced dermal elastin and fibrillin-1 staining and altered TGF-β1 binding, and represents a novel TNXA/TNXB chimera. Tenascin-X protein expression was normal in dermal fibroblasts, suggesting a dominant-negative effect. CONCLUSIONS: CAH-X syndrome is commonly found in CAH due to 21-hydroxylase deficiency and may result from various etiological mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The CAH-X prevalence was 15.6% (21/135 probands), higher than the previously estimated 8.5%, and was particularly high (29.2% or 21/72) in those with a 30-Kb deletion.”
From High-Throughput Screening for CYP21A1P-TNXA/TNXB Chimeric Genes Responsible for Ehlers Danlos Syndrome in Patients with Congenital Adrenal Hyperplasia. (2019) · cites this paper as [13]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies struggled to define its genetic etiology but without compelling evidence, corroborating the hypothesis of a high genetic heterogeneity of the condition [112,113,114,115].”
From Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes (2019) · cites this paper as [114]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This rare chimera is characterized by a 120-bp deletion in exon 35 of TNXB and results in TNXB haploinsufficiency and disrupted TGF-β signaling; when found in the homozygous state, it leads to a contiguous gene syndrome consisting of CAH and Ehlers-Danlos syndrome (EDS) [7, 31].”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two most common genetic causes of CAH-X are CYP21A1P-TNXA/TNXB chimeras with pseudogene TNXA substitution for TNXB exons 35–44 (CAH-X CH-1) and TNXB exons 40–44 (CAH-X CH-2).”
From Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“missense mutations in TNX have been found in vesicoureteral reflux [65,66].”
From Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome (2018) · cites this paper as [66]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
Loeys, B. L., Chen, J., Neptune, E. R., Judge, D. P., Podowski, M., Holm, T., Meyers, J., Leitch, C. C., Katsanis, N., Sharifi, N., et al. (2005) · Nature Genetics · doi:10.1038/ng1511 · Cited by 1,795
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 2×
“Hypermobile small (1) and large joints (2), and umbilical hernia (3).”
BackgroundSelf-citationSimons, K. T., Kooperberg, C., Huang, E., & Baker, D. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0959 · Cited by 1,396 · cited 2×
“org) for domain (Ginzu) (21) and tertiary structure predictions (Rosetta) (22, 23).”
BackgroundMethodCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationLoss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm
Lindsay, M. E., Schepers, D., Bolar, N. A., Doyle, J. J., Gallo, E., Fert-Bober, J., Kempers, M. J. E., Fishman, E. K., Chen, Y., Myers, L., et al. (2012) · Nature Genetics · doi:10.1038/ng.2349 · Cited by 482
A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency
Schalkwijk, J., Zweers, M. C., Steijlen, P. M., Dean, W. B., Taylor, G., van Vlijmen, I. M., van Haren, B., Miller, W. L., & Bristow, J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002939 · Cited by 391
Tenascin-X deficiency is associated with Ehlers-Danlos syndrome
Burch, G. H., Gong, Y., Liu, W., Dettman, R. W., Curry, C. J., Smith, L., Miller, W. L., & Bristow, J. (1997) · Nature Genetics · doi:10.1038/ng0997-104 · Cited by 366 · cited 17×
“To rule out possible pathogenic variants in other known EDS associated genes, we sequenced the COL3A1, COL5A1, and COL5A2 genes in the 10 novel CAH-X patients and found no pathogenic or likely pathogenic variants.”
BackgroundInfluential
Cited by
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationTinkle, B., Castori, M., Berglund, B., Cohen, H., Grahame, R., Kazkaz, H., & Levy, H. (2017) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31538 · Cited by 499
Genetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
The Ehlers–Danlos syndromes, rare types
Brady, A. F., Demirdas, S., Fournel‐Gigleux, S., Ghali, N., Giunta, C., Kapferer‐Seebacher, I., Kosho, T., Mendoza‐Londono, R., Pope, M. F., Rohrbach, M., et al. (2017) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31550 · Cited by 258
“They concluded that the CAH-X syndrome is commonly found in CAH due to 21hydroxylase deficiency and may result from various etiological mechanisms [Morissette et al., 2015].”
BackgroundGensemer, C., Burks, R., Kautz, S. A., Judge, D. P., Lavallee, M. E., & Norris, R. A. (2020) · Developmental Dynamics · doi:10.1002/dvdy.220 · Cited by 182
Kucharik, A. H., & Chang, C. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08755-8 · Cited by 122
Genetics of Congenital Adrenal Hyperplasia
Hannah-Shmouni, F., Chen, W., & Merke, D. P. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.008 · Cited by 97
Self-citationChiarelli, N., Ritelli, M., Zoppi, N., & Colombi, M. (2019) · Genes · doi:10.3390/genes10080609 · Cited by 82
Aubry-Rozier, B., Schwitzguebel, A., Valerio, F., Tanniger, J., Paquier, C., Berna, C., Hügle, T., & Benaim, C. (2021) · Rheumatology International · doi:10.1007/s00296-021-04968-3 · Cited by 66
“Despite a probable autosomal dominant inheritance [11] and reports of haploinsufficiency or missense of tenascin X in a few cases [12, 13], no gene has been identified for hEDS [11, 14].”
BackgroundTenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome
Miller, W. L., & Merke, D. P. (2018) · Hormone Research in Paediatrics · doi:10.1159/000481911 · Cited by 61
Self-citationDemirdas, S., Dulfer, E., Robert, L., Kempers, M., van Beek, D., Micha, D., van Engelen, B. G., Hamel, B., Schalkwijk, J., Loeys, B., et al. (2017) · Clinical Genetics · doi:10.1111/cge.12853 · Cited by 60
“This suggests that the endocrine milieu of Congenital Adrenal Hyperplasia (CAH) influences the severity of EDS (14, 15).”
BackgroundInfluentialBaronio, F., Ortolano, R., Menabò, S., Cassio, A., Baldazzi, L., Natale, V. D., Tonti, G., Vestrucci, B., & Balsamo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184605 · Cited by 60
“5% of patients with CAH [73,74], but this figure has recently been reported to be around 15.”
BackgroundInfluentialLatent TGF-β Activation Is a Hallmark of the Tenascin Family
Aubert, A., Mercier‐Gouy, P., Aguero, S., Berthier, L., Liot, S., Prigent, L., Alcaraz, L. B., Verrier, B., Terreux, R., Moali, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613438 · Cited by 47
“12174C>G mutation that reduces the binding affinity of latent TGF-b to the native TN-X (54).”
BackgroundChen, W., Perritt, A. F., Morissette, R., Dreiling, J. L., Bohn, M.-F., Mallappa, A., Xu, Z., Quezado, M., & Merke, D. P. (2016) · Human Mutation · doi:10.1002/humu.23028 · Cited by 45
“…2013; Morissette et al., 2014]; CAH-X CH-2 involves the c.12174C>G (p.Cys4058Trp) variant in exon 40 of TNXB, which does not alter TNX expression but rather causes a dominant-negative effect due to the loss of a critical disulfide bond in the TNX fibrinogen-like domain [Morissette et al., 2015].”
BackgroundMethodResultInfluentialSelf-citationUpdates in Clinical and Genetics Aspects of Hypermobile Ehlers Danlos Syndrome
Forghani, I. (2018) · Balkan Medical Journal · doi:10.4274/balkanmedj.2018.1113 · Cited by 40
“(31) found a heterozygous missense variant, c.”
Genes and Pseudogenes: Complexity of the RCCX Locus and Disease
Carrozza, C., Foca, L., De Paolis, E., & Concolino, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.709758 · Cited by 37
“In addition, compared to haploinsufficiency, a dominant-negative effect causes a more severe phenotype displayed by greater skin and joint involvement (74).”
BackgroundInfluentialGao, Y., Lu, L., Yu, B., Mao, J., Wang, X., Nie, M., & Wu, X. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa199 · Cited by 31
Green, C. E., Ghali, N., Akilapa, R., Angwin, C., Baker, D., Bartlett, M., Bowen, J. M., Brady, A. F., Brock, J., Chamberlain, E. D., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0850-1 · Cited by 31
Lao, Q., Brookner, B., & Merke, D. P. (2019) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.001 · Cited by 29
“Subjects with clinical manifestations of EDS were also subjected to a validated Sanger-based test of TNX chimeras (Prevention Genetics).(12,13)”
BackgroundMethodSelf-citationTenascin-X—Discovery and Early Research
Miller, W. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612497 · Cited by 26
“Deborah Merke (NIH, BethesdaMD) found that 7% of patients with 21OHD had symptomatic TNX haploinsufficiency (70, 71), and a recent study reported 14% (72); this association is now regarded as a subtype of 21OHD termed CAH-X (73).”
BackgroundAli, A. A., Andrzejowski, P., Kanakaris, N. K., & Giannoudis, P. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123992 · Cited by 25
“Haploinsufficiency and missense variants of tenascin-X, which is an extracellular matrix protein encoded by the TNXB gene, has been reported in a handful of hEDS phenotype individuals [51,52].”
BackgroundKim, H., Shim, Y., Lee, T. G., Won, D., Choi, J. R., Shin, S., & Lee, S. (2022) · Clinical Genetics · doi:10.1111/cge.14236 · Cited by 24
“28,29 32 Similar to other bioinformatic tools that use the read-depth approach, CABANA seems to have difficulty in determining true CNVs in regions with high GC content, where highly variable NRDs tend to appear.”
Biomarkers for Ehlers-Danlos Syndromes: There Is a Role?
Caliogna, L., Guerrieri, V., Annunziata, S., Bina, V., Brancato, A. M., Castelli, A., Jannelli, E., Ivone, A., Grassi, F. A., Mosconi, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810149 · Cited by 24
Marino, R., Garrido, N. P., Ramirez, P., Notaristéfano, G., Moresco, A., Touzon, M. S., Vaiani, E., Finkielstain, G., Obregón, M. G., Balbi, V., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab033 · Cited by 23
Novel TNXB Variants in Two Italian Patients with Classical-Like Ehlers-Danlos Syndrome
Micale, L., Guarnieri, V., Augello, B., Palumbo, O., Agolini, E., Sofia, V. M., Mazza, T., Novelli, A., Carella, M., & Castori, M. (2019) · Genes · doi:10.3390/genes10120967 · Cited by 23
“In particular, CAH-X chimera 1 (CH-1) and CAH-X chimera 2 (CH-2) have TNXB exons 35–44 and 40–44, respectively, replaced with TNXA [4,9,10].”
BackgroundInfluentialCongenital Adrenal Hyperplasia and Ehlers-Danlos Syndrome
Marino, R. M., Moresco, A., Garrido, N. P., Ramírez, P., & Belgorosky, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.803226 · Cited by 23
“Some carriers were observed to have less joint, heart, or gastrointestinal symptoms, while others were asymptomatic (12, 13, 17, 19, 20).”
BackgroundInfluentialLao, Q., & Merke, D. P. (2021) · European Journal of Human Genetics · doi:10.1038/s41431-021-00870-5 · Cited by 23
“patients have more severe EDS manifestations than their carrier counterparts [4, 5].”
BackgroundSelf-citationEhlers-Danlos Syndromes, Joint Hypermobility and Hypermobility Spectrum Disorders
Micale, L., Fusco, C., & Castori, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-80614-9_9 · Cited by 21
Yang, M., & White, P. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae535 · Cited by 20
“CAH-X is associated with joint hypermobility, chronic arthralgia, joint subluxations, hernias, and cardiac defects (96).”
Kim, J. H., Kim, G.-H., Yoo, H., & Choi, J. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2346108.054 · Cited by 20
Hypermobile Disorders and Their Effects on the Hip Joint
Clapp, I. M., Paul, K. M., Beck, E. C., & Nho, S. J. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.596971 · Cited by 20
“Recently, new genes coding for LZTS1 (32) and Tenascin X protein—a protein that plays an important role in organizing and maintaining the structure of connective tissues (33, 34)—were associated with the hEDS phenotype.”
BackgroundCAH-X Syndrome: Genetic and Clinical Profile
Concolino, P., & Falhammar, H. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00588-0 · Cited by 19
“The aim of this review is to present the genetic and clinical profile of CAH-X syndrome from the currently available literature. was certainly provided by the National Institutes of Health [22, 28, 31].”
BackgroundInfluentialAn overview of inborn errors of metabolism manifesting with primary adrenal insufficiency
Hannah‐Shmouni, F., & Stratakis, C. A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9447-2 · Cited by 18
“The prevalence of CAH-X amongst patients with salt-wasting CAH is approximately 10% [64].”
BackgroundParagliola, R. M., Perrucci, A., Foca, L., Urbani, A., & Concolino, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133818 · Cited by 17
“In contrast, CH-2 and CH-3 chimeras, carrying missense pathogenic variants, are associated with a dominant-negative effect [15,16].”
BackgroundLao, Q., Mallappa, A., Faucz, F. R., Joyal, E., Veeraraghavan, P., Chen, W., & Merke, D. P. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1556 · Cited by 17
“It is also notable that although the two pathogenic CAH-X chimeras (CH-1 and CH-2) cause EDS in an autosomal dominant manner regardless of the CAH status, the EDS manifestations are usually milder in CAH carriers compared to CAH patients, suggesting potential hormonal effects on the EDS phenotype (Merke et al., 2013;…”
BackgroundSelf-citationLong-Read Sequencing Solves Complex Structure of CYP21A2 in a Large 21-Hydroxylase Deficiency Cohort
Wang, R., Luo, X., Sun, Y., Liang, L., Mao, A., Lu, D., Zhang, K., Yang, Y., Sun, Y., Sun, M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae519 · Cited by 16
Paragliola, R. M., Perrucci, A., Foca, L., Urbani, A., & Concolino, P. (2022) · doi:10.20944/preprints202206.0329.v1 · Cited by 13
Pezaro, S., Brock, I., Buckley, M., Callaway, S., Demirdas, S., Hakim, A. J., Harris, C. L., Gross, C. H., Karanfil, M., Ray, I. L., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302401 · Cited by 13
Zhang, R., Cui, D., Song, C., Ma, X., Cai, N., Zhang, Y., Feng, M., Cao, Y., Chen, L., & Qiang, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117820 · Cited by 13
Lao, Q., Jardin, M. D., Jayakrishnan, R., Ernst, M., & Merke, D. P. (2018) · Human Genetics · doi:10.1007/s00439-018-1959-z · Cited by 12
Self-citationConcolino, P., & Falhammar, H. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf018 · Cited by 12
“The prevalence of CAH-X is approximately 11% to 15% in large cohorts of patients with 21OHD, and clinical manifestations of the disease have been described for different populations [48, 64, 68, 69].”
Jayakrishnan, R., Lao, Q., Adams, S. D., Ward, W. W., & Merke, D. P. (2018) · Gene · doi:10.1016/j.gene.2018.11.023 · Cited by 10
Self-citationYamaguchi, T., Yamada, K., Nagai, S., Nishikubo, T., Koitabashi, N., Minami‐Hori, M., Matsushima, M., Shibata, Y., Ishiguro, H., Sanai, H., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1234804 · Cited by 9
“(Cys4058Trp) in exon 40 (Figure 1B) are indices of TNXA-derived variations (Morissette et al., 2015), and have been determined to be pathogenic (Demirdas et al.”
BackgroundKolli, V., Kim, H., Rao, H., Lao, Q., Gaynor, A., Milner, J. D., & Merke, D. P. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4753-7 · Cited by 9
Self-citationCardenas, S. M. C., El-Kaissi, S., Jarad, O., Liaqat, M., Korbonits, M., & Hamrahian, A. H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa077 · Cited by 8
“5% in patients with CAH resulting from 21-hydroxylase deficiency [26].”
BackgroundFanis, P., Skordis, N., Toumba, M., Picolos, M. K., Tanteles, G. A., Neocleous, V., & Phylactou, L. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156616 · Cited by 8
Lao, Q., Schulman, A., Kulkarni, S., Kollender, S., Bick, D., Moon, A., Burkardt, D. D., & Merke, D. P. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf546 · Cited by 6
Self-citationSantoreneos, R., Vakulin, C., Ellul, M., Rawlings, L. H., Hardy, T., & Poplawski, N. K. (2022) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62674 · Cited by 5
“Approximately 9% of patients with CAH due to 21-hydroxylase deficiency have an associated connective tissue disorder due to a contiguous gene deletion affecting the TNXB gene and CYP21A2[21B] gene (Morissette et al., 2015).”
BackgroundFanis, P., Skordis, N., Phylactou, L. A., & Neocleous, V. (2023) · HORMONES · doi:10.1007/s42000-022-00410-w · Cited by 4
“In this study, we present the genetic features of the disease in a family of Cypriot descent with the salt-wasting (SW) classic form as a result of the TNXA/TNXB chimera, resulting in deletions of CYP21A2 and TNXB in one allele [7, 15] and a severe case of CYP21A2 mutation in the second allele.”
BackgroundInfluentialFigueras, L. M., Muñoz‐Pacheco, R., González, D. G., Arriba, M., & Zubicaray, B. E. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0071 · Cited by 4
“8) c.12174C>G (p.Cys4058Trp) in exon 40 [20].”
BackgroundChong, H., Xue, G., Pi, Y., Zhang, Y., Li, Y., Xing, Y., Chen, B., & Zhang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1665306 · Cited by 3
Genomic complexity and clinical significance of the RCCX locus
Shiryagin, V. V., Deviatkin, A. A., Fateev, O. D., Petriaikina, E. S., Bogdanov, V. P., Antysheva, Z., Volchkov, P., Yudin, S. M., Woroncow, M. V., & Skvortsova, V. I. (2024) · PeerJ · doi:10.7717/peerj.18243 · Cited by 3
“Overall, about 10% of CAH cases are CAH-X syndromes ( Morissette et al., 2015 ).”
BackgroundFigueras, L. M., Muñoz‐Pacheco, R., González, D. G., Arriba, M., & Zubicaray, B. E. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0050 · Cited by 2
“8) c.12174C>G (p.Cys4058Trp) del exón 40 [20].”
BackgroundKim, S., Yoon, J., Kim, D., Park, S., Kim, G.-H., Yoo, H., Choi, J., Kim, J., & Kim, J. H. (2025) · medRxiv · doi:10.1101/2025.07.09.25331238 · Cited by 2
Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X
Lao, Q., Zhou, K., Parker, M., Faucz, F. R., & Merke, D. P. (2023) · Genes · doi:10.3390/genes14020265 · Cited by 1
“However, in general, CAH patients suffer more connective tissue dysplasia phenotype than their carrier counterparts, possibly due to the influence of chronic glucocorticoid exposure [7,8,11,28].”
BackgroundSelf-citationFinkielstain, G. P., Jha, S., & Merke, D. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817962-8.00008-1 · Cited by 1
Self-citationIvo, C. R., Fitas, A. L., Madureira, I., Diamantino, C., Gomes, S., Gonçalves, J., & Lopes, L. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0396 · Cited by 1
Bondarenko, A. S., Mamedova, E., Belaya, Z. E., & Mel'nichenko, G. A. (2024) · Obesity and metabolism · doi:10.14341/omet13015 · Cited by 1
Ihinger, J. M. (2019) · eScholarship (California Digital Library) · Cited by 1
Diagnosing CAH-X syndrome by long-read sequencing and identifying a novel genotype
Li, Z., Xu, S., Fu, Q., Du, L., Lin, Q., Lin, H., E., H., & Liu, H. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04356-9
“1) [4, 5, 15].”
Survey Validation for Screening of Hypermobile Ehlers-Danlos Syndrome
Quinlan, M. (2018) · OhioLink ETD Center (Ohio Library and Information Network)
The search for candidate genes associated with hypermobile Ehlers-Danlos syndrome
Serebryakova, E. A., Kadurina, T. I., Lonishin, L., Николаевна, А. Л., Барбитов, Ю. А., Polev, D. E., Glotov, O. S., & Glotov, A. S. (2020) · Nauchno-prakticheskii zhurnal «Medicinskaia genetika» · doi:10.25557/2073-7998.2020.08.54-56
Baumgartner-Parzer, S. M., & Schernthaner-Reiter, M. H. (2021) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-021-00150-z
Ehlers-Danlos syndrome: From bedside to bench
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4557-7
Genetics of Congenital Adrenal Hyperplasia
Rao, S., & Walia, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-1639-5_29
Congenital Adrenal Hyperplasia
Witchel, S. F., Oberfield, S. E., Fisher, A. S., & Trapp, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_11
Analysis of Referrals to Genetics for Suspected Hypermobile Ehlers-Danlos Syndrome
Sugiura, H. (2023) · eScholarship (California Digital Library)
Novel cardiac abnormalities observed in CAH patients with tenascin-X haploinsufficiency
Sappl, A., Sriramachandran, A. M., Lottspeich, C., Vill, K., Morak, M., Welp, A.-C., Dervishi, O., Bidlingmaier, M., Kunz, S. L., & Reisch, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1797669
Дорош, О., Левінтанус, В., Feskova, A., Feskov, O. M., Feskova, I., Konoplia, L., & Герасименко, Л. В. (2026) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2026.2.09
Xia, Y., Cui, D., Li, D., Chen, L., Chen, X., Wu, S., Mao, A., & Kong, X. (2026) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2026.08.004
Molecular resolution of a TNXA / TNXB CH-1 chimera and the non-chimeric TNXB allele in CAH-X
Erkan, D. D., Özalkak, Ş., Lafcı, N. G., & Çetinkaya, S. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-26-0085
Yamaguchi, T., Yamada, K., Nagai, S., Nishikubo, T., Koitabashi, N., Minami-Hori, M., Matsushima, M., Shibata, Y., Ishiguro, H., Sanai, H., et al. (2023) · doi:10.3389/fgene.2023.1234804.s002
Metadata
- Authors
- Morissette, R., Chen, W., Perritt, A. F., Dreiling, J. L., Arai, A. E., Sachdev, V., Hannoush, H., Mallappa, A., Xu, Z., McDonnell, N. B., Quezado, M., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Morissette, Rachel
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- E1143-E1152
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4525000
- OpenAlex
- W1952841488
- Cited by
- 68
- References
- 39
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 2
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Ehlers-Danlos syndrome, congenital adrenal hyperplasia, contiguous gene syndrome, tenascin-X, TNXB, 21-hydroxylase deficiency, CYP21A2, missense mutations, fibrillin-1, dominant negative effect
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Aged, Child, Child, Preschool, Ehlers-Danlos Syndrome, Female, Humans, Infant, Male, Middle Aged, Phenotype, Cohort Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.